HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus HighTide Therapeutics Inc. Oct 31, 2025 08:30 HKT/SGT Read More
全球首创抗炎代谢调节剂HTD1801完成2型糖尿病III期临床研究 展现持续52周的综合获益与安全性优势 HighTide Therapeutics Inc. Oct 31, 2025 08:30 HKT/SGT Read More
全球首創抗炎代謝調節劑HTD1801完成2型糖尿病III期臨床研究 展現持續52周的綜合獲益與安全性優勢 HighTide Therapeutics Inc. Oct 31, 2025 08:30 HKT/SGT Read More
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China China Medical System Holdings Limited Oct 30, 2025 21:00 JST Read More
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China China Medical System Holdings Limited Oct 30, 2025 20:00 HKT/SGT Read More
康哲药业(867.HK;8A8.SG)长效抗IL-4Rα人源化单抗注射液MG-K10特应性皮炎适应症中国NDA已获受理 China Medical System Holdings Limited Oct 30, 2025 18:27 HKT/SGT Read More
康哲藥業(867.HK;8A8.SG)長效抗IL-4Rα人源化單抗注射液MG-K10特應性皮炎適應症中國NDA已獲受理 China Medical System Holdings Limited Oct 30, 2025 18:27 HKT/SGT Read More
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma Eisai Oct 30, 2025 13:43 HKT/SGT Read More
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma Eisai Oct 28, 2025 23:30 HKT/SGT Read More
康哲藥業(867.HK; 8A8.SG)簽訂眼科藥物諾適得(R)與倍優適(R)經銷協議 China Medical System Holdings Limited Oct 28, 2025 18:22 HKT/SGT Read More
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R) China Medical System Holdings Limited Oct 27, 2025 23:00 JST Read More
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R) China Medical System Holdings Limited Oct 27, 2025 22:00 HKT/SGT Read More
康哲药业(867.HK; 8A8.SG)签订眼科药物诺适得(R)与倍优适(R)经销协议 China Medical System Holdings Limited Oct 27, 2025 18:29 HKT/SGT Read More
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 Everest Medicines Limited Oct 14, 2025 17:38 HKT/SGT Read More
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication China Medical System Holdings Limited Sep 28, 2025 16:00 JST Read More
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication China Medical System Holdings Limited Sep 28, 2025 15:00 HKT/SGT Read More
康哲藥業(867.HK;8A8.SG)創新藥磷酸蘆可替尼乳膏AD中國三期臨床取得積極結果 China Medical System Holdings Limited Sep 28, 2025 11:33 HKT/SGT Read More
康哲药业(867.HK;8A8.SG)创新药磷酸芦可替尼乳膏AD中国三期临床取得积极结果 China Medical System Holdings Limited Sep 28, 2025 11:33 HKT/SGT Read More
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies China Medical System Holdings Limited Sep 23, 2025 13:15 JST Read More